Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 7/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22494202 | 0.81 | CYP2C9 (0.50) | CYP2C9CYP2C19CYP3A4DYRK1AMEN1 | |
| SCHEMBL16975844 | 0.81 | CYP2C9 (0.50) | CYP2C9CYP2C19CYP3A4DYRK1AMEN1 | |
| SCHEMBL4941214 | 0.77 | CYP2C9 (0.47) | CYP2C9CYP2C19CYP3A4DYRK1AMEN1 | |
| SCHEMBL30802190 | 0.77 | CYP2C9 (0.47) | CYP2C9CYP2C19CYP3A4DYRK1AMEN1 | |
| SCHEMBL5136165 | 0.77 | CYP2C9 (0.47) | CYP2C9CYP2C19CYP3A4DYRK1AMEN1 | |
| SCHEMBL20958435 | 0.75 | NAAA (0.38) | CYP2C9PROKR1FPR2ALDH1A1 | |
| SCHEMBL16324387 | 0.72 | PROKR1 (0.44) | CYP2C9CYP2C19MEN1KMT2AMAPK1 | |
| SCHEMBL16325018 | 0.72 | MEN1 (0.35) | CYP2C9CYP2C19MEN1KMT2AMAPK1 | |
| SCHEMBL23703198 | 0.72 | CYP2C9 (0.44) | CYP2C9CYP2C19CYP3A4DYRK1AMEN1 | |
| SCHEMBL10922758 | 0.69 | KDM4E (0.41) | LMNAPKMKDM4EHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240252486-A1 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | UNIV CALIFORNIA (US) | 2024-08-01 | — | — | US | disclosed |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| WO-2022204140-A1 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4013762-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
| CN-101291914-A | Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | CN | disclosed |
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| EP-1651608-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009964-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026952-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| US-6333338-B1 | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | LABORATOIRE L. LAFON (FR) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | CYP2C9 49/4885CYP2C19 40/4885CYP3A4 3/4885 |
| US-20230073334-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | CYP2C9 4185/4885CYP2C19 2097/4885CYP3A4 3129/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | CYP2C9 59/4885CYP2C19 71/4885CYP3A4 6/4885 |
| US-20050026952-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CYP2C9 767/4885CYP2C19 500/4885CYP3A4 235/4885 |
| US-12054474-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | CYP2C9 4185/4885CYP2C19 2097/4885CYP3A4 3129/4885 |
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | NR3C1, NR3C2, MC2R | CYP2C9 314/4885CYP2C19 286/4885CYP3A4 657/4885 |
| US-11512066-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | CYP2C9 4361/4885CYP2C19 2422/4885CYP3A4 3405/4885 |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | CYP2C9 1534/4885CYP2C19 1728/4885CYP3A4 901/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP2C9 4782/4885CYP2C19 4200/4885CYP3A4 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.